Celldex Therapeutics (CLDX) Total Debt (2010 - 2013)

Celldex Therapeutics' Total Debt history runs 4 years deep, the most recent figure standing at $10.1 million for Q1 2013.

• In Q1 2013, Total Debt fell 33.77% year-over-year to $10.1 million; the TTM figure through Mar 2013 stood at $10.1 million (down 33.77% YoY), while the FY2012 annual figure was $11.3 million, down 25.13% from the prior year.
• Total Debt was $10.1 million for Q1 2013 at Celldex Therapeutics, down from $11.3 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $19.2 million in Q2 2012 to a low of $10.0 million in Q4 2010.
• Historically, Total Debt has averaged $13.9 million across 4 years, with a median of $15.0 million in 2011.
• The sharpest annual moves came in 2011 and 2013: Total Debt jumped 51.44% in 2011, then slumped 33.77% in 2013.
• A 4-year view of Total Debt shows it stood at $10.0 million in 2010, then surged by 51.44% to $15.1 million in 2011, then slipped by 25.13% to $11.3 million in 2012, then fell by 11.31% to $10.1 million in 2013.
• The last three Total Debt figures came in at $10.1 million (Q1 2013), $11.3 million (Q4 2012), and $12.6 million (Q3 2012), per Business Quant data.